



ABB10010P0470US (OZ-50061)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1614  
11  
10/25/03  
C style  
RECEIVED  
OCT 22 2003  
TECH CENTER 1600/2900

In Re Application Of: ) Benzodiazepine Derivatives, the Production  
Lubisch et al. ) and Use Thereof  
Serial No.: 10/088,604 )  
Filed: July 1, 2002 ) Group Art Unit: 1614  
 ) Examiner: Bruck Kifle

**RESPONSE TO RESTRICTION REQUIREMENT**

Commissioner for Patents  
BOX RESPONSES NO-FEE  
Alexandria, Virginia 22313-1450

Sir:

In response to the Restriction Requirement dated September 23, 2003, Applicants elect Group II (compounds and uses of Formula (I) where A is C<sub>2</sub>) with traverse.

Applicants traverse this Restriction Requirement on the grounds that there is a "single structural element that is shared by all of the alternatives", i.e., the compounds are all benzodiazepine derivatives and they also have the same utility.

Reconsideration of this Restriction Requirement is respectfully requested.

Respectfully submitted,

WOOD, PHILLIPS, KATZ, CLARK & MORTIMER

  
Martin L. Katz, Reg. No. 25,011

Date: October 17, 2003

Citicorp Center  
500 West Madison Street  
Suite 3800  
Chicago, IL 60661  
(312) 876-1800



ABB10010P0470US (OZ-50761)

37 CFR 1.8  
CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service, as first class mail in an envelope addressed to Commissioner for Patents, Box No-Fee, Alexandria, Virginia 22313-1450 on October 17, 2003.

A handwritten signature in cursive script, reading "Rebecca J. Willis", written over a horizontal line.

Rebecca J. Willis